Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Short Interest Up 7.7% in December

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) was the recipient of a significant increase in short interest in December. As of December 15th, there was short interest totalling 119,200 shares, an increase of 7.7% from the November 30th total of 110,700 shares. Approximately 0.7% of the company’s stock are short sold. Based on an average trading volume of 33,100 shares, the days-to-cover ratio is presently 3.6 days.

Cyclo Therapeutics Stock Performance

CYTH stock remained flat at $0.59 during trading on Thursday. 1,611 shares of the company were exchanged, compared to its average volume of 65,934. The firm has a market cap of $16.97 million, a P/E ratio of -0.66 and a beta of -0.46. Cyclo Therapeutics has a one year low of $0.55 and a one year high of $2.12. The business has a fifty day simple moving average of $0.67 and a 200-day simple moving average of $0.87.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.